Ministry of Food and Drug Safety begins investigation into hyperlipidemia treatment that Daewon Pharmaceutical is producing on consignment

Reporter Kim Jisun / approved : 2023-10-13 03:07:11
  • -
  • +
  • 인쇄

 

[Alpha Biz=(Chicago) Reporter Kim Jisun] The Ministry of Food and Drug Safety has launched an investigation into the cause of the report that other drugs are included in the hyperlipidemia treatment "Rosuvastatin" of Dongkuk Pharmaceutical, which is being commissioned by Daewon Pharmaceutical.

According to the Ministry of Food and Drug Safety on the 12th, a report was recently received that a digestive medicine product was found in the Rosuvastatin product box. There are two packages of Rosuvastatin, 15 pills each, one of which was for stomach medicine.

Rosuvastatin, a hyperlipidemia complex of Dongkuk Pharmaceutical, is a product commissioned by Daewon Pharmaceutical at Hyangnam Plant in Hwaseong, Gyeonggi-do.

Daewon Pharmaceutical Co. said it is conducting a full investigation into the manufacturing line that produced the product on the same day and Dongkuk Pharmaceutical Co. is recalling the product.

 

Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)

어플

주요기사

Dongwon F&B Ordered to Revise Unfair Dealer Contract Terms2025.12.23
Coupang Files Lawsuit Challenging Industrial Accident Ruling in Death of Warehouse Worker2025.12.23
Cho Hyun-bum, Chairman of Hankook & Company, Sentence Reduced to Two Years on Embezzlement and Breach of Trust Charges2025.12.23
Korea’s Tax Authority Launches Special Tax Probe into Coupang2025.12.23
Hanwha Qcells Briefly Filed, Then Withdrew U.S. Tariff Refund Lawsuit Citing Law Firm Error2025.12.23
뉴스댓글 >

건강이 보이는 대표 K Medical 뉴스

HEADLINE

PHOTO

많이 본 기사